Dataset from BAX 855 (PEGylated Recombinant Factor VIII): A Phase 1, Prospective, Open Label, Cross-Over, Dose-Escalation Study in Previously Treated Patients (PTPs) With Severe (FVIII < 1%) Hemophilia A
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00008437
下载链接
链接失效反馈官方服务：
资源简介：
The objectives of this study are to assess the tolerability and safety after single dose
treatments of BAX 855 in previously treated patients (PTPs) with severe hemophilia A, to
determine the pharmacokinetic (PK) parameters of BAX 855 compared in crossover with ADVATE,
and to evaluate the impact of anti-polyethylene glycol (PEG) antibodies on PK parameters.
创建时间：
2024-11-26
